Optima Health PLC (OPT) AI Stock Analysis

• Market Cap: £190.87M
• Dividend Yield: N/A
• Average Volume (3M): 135.53K
• Price to Earnings (P/E): 54.2
• Beta (1Y): -0.19
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: UK
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Care Facilities
• EPS (TTM): 0.00
• Shares Outstanding: 88,776,220
• 10 Day Avg. Volume: 155,484
• 30 Day Avg. Volume: 135,525
• PEG Ratio: -0.14
• Price to Book (P/B): 0.52
• Price to Sales (P/S): 0.84
• P/FCF Ratio: -82.58
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: £240.00
• Price Target Upside: 22.45% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 53 Neutral
• Price Target: 228.00p ▲(16.33% Upside)

The score is held back primarily by weakened cash generation (negative free cash flow in 2025) and a high valuation (P/E ~50) despite only thin margins. Financial performance shows improvement with a return to profitability and modest leverage, but volatility reduces confidence. Technical signals are mixed with neutral momentum and the price below longer-term averages.

Positive Factors

Revenue Growth & Scale

A material revenue step-up to ~£105m in 2025 signals the company has won scale and larger contract volumes. Sustained higher top-line provides a base to spread fixed costs, invest in service capability, and negotiate with large employer clients, supporting longer-term growth potential.

Return to Profitability

Returning to operating profit and net income after prior losses shows operational recovery and management ability to restore margins. Durable profitability enables reinvestment, debt reduction or strategic hires, improving the company's capacity to execute on long-term contracts and service expansion.

Manageable Leverage / Strong Equity Base

Low debt relative to equity and a sizeable equity base provide financing flexibility and lower solvency risk. This capital structure supports bidding on multi-year employer contracts and absorbing short-term cash swings without forcing dilutive financing, underpinning medium-term stability.

Negative Factors

Weak Cash Generation

Negative free cash flow despite positive earnings indicates poor cash conversion or higher working-capital and investment needs. Over the medium term this raises funding and execution risk, limits capacity for organic investment in services, and may force external financing at inopportune times.

Earnings Volatility

Recurrent swings between profit and loss show underlying revenue or cost instability. Persistent volatility undermines predictable cash flows, complicates pricing and contract renewal discussions with employers, and raises the likelihood of future earnings shocks that could impair strategic execution.

Thin Net Margins

A ~1.6% net margin leaves limited buffer against cost inflation or contract pricing pressure. Structurally low profitability constrains reinvestment and makes it harder to build durable competitive advantages in clinical services, reducing resilience to industry pricing competition over the medium term.

Optima Health PLC Business Overview & Revenue Model

Company Description

Optima Health Plc provides occupational health and wellbeing services. It offers Engagement and Wellbeing, mental health and musculoskeletal services. The company was founded in 1947 and is headquartered in Sheffield, the United Kingdom.

How the Company Makes Money

Optima Health PLC Financial Statement Overview

Summary

Profitability improved in 2025 with positive operating profit and net income, and leverage looks modest in the latest year. However, earnings have been volatile (losses in 2022 and 2024), net margin remains thin (~1.6% in 2025), and cash flow deteriorated with negative free cash flow in 2025, raising durability and funding-risk concerns.

Income Statement

Revenue expanded sharply in 2025 (to ~£105.0m) after a very large step-up from 2022 to 2023, but growth has not been steady (slight decline in 2024). Profitability improved in 2025 with positive operating profit and net income, and EBITDA margin strengthened versus 2024; however, net margin remains thin (~1.6% in 2025) and results have been volatile with losses in 2022 and 2024, which limits confidence in durability.

Balance Sheet

Leverage appears manageable in the latest year with low debt relative to equity (debt-to-equity ~0.13 in 2025) and a large equity base versus total assets. That said, the capital structure picture is clouded by 2024 showing equity at zero (making year-over-year comparability and leverage signals less reliable), and returns on equity remain low (~1.0% in 2025), indicating the balance sheet is not yet translating into strong shareholder returns.

Cash Flow

Cash generation weakened materially in 2025: operating cash flow fell to ~£2.7m and free cash flow turned negative (~-£1.1m) despite positive earnings, implying cash conversion issues and/or elevated investment/working-capital needs. Prior years show better cash support (notably 2024 with strong positive operating and free cash flow), but the sharp swing back to negative free cash flow introduces higher near-term funding and execution risk.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	113.75M	105.05M	110.89M	115.35M	22.39M
Gross Profit	24.41M	33.04M	36.47M	36.94M	8.04M
EBITDA	16.42M	13.65M	10.06M	11.06M	1.74M
Net Income	3.53M	1.65M	-1.08M	1.59M	-246.00K
Balance Sheet
Total Assets	221.43M	218.14M	210.39M	225.27M	192.56M
Cash, Cash Equivalents and Short-Term Investments	8.27M	14.80M	8.22M	12.73M	6.90M
Total Debt	19.40M	21.68M	12.45M	57.87M	34.06M
Total Liabilities	51.97M	50.02M	48.11M	97.24M	66.25M
Stockholders Equity	169.45M	168.12M	0.00	128.03M	126.31M
Cash Flow
Free Cash Flow	7.93M	-1.06M	10.00M	2.40M	-1.63M
Operating Cash Flow	9.76M	2.69M	12.85M	6.59M	-836.00K
Investing Cash Flow	-11.76M	-5.65M	-2.85M	843.00K	7.77M
Financing Cash Flow	880.00K	-3.33M	-1.63M	-1.61M	-205.00K

Optima Health PLC Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
CRW	69 Neutral	£590.50M	38.70	6.00%	1.66%	5.74%	63.23%
AMS	69 Neutral	£466.31M	50.71	3.66%	1.25%	68.03%	-18.27%
CTEC	68 Neutral	£4.48B	28.08	12.73%	2.11%	4.18%	37.65%
CVSG	66 Neutral	£916.24M	48.55	6.75%	0.67%	4.00%	-6.98%
SPI	55 Neutral	£820.84M	44.35	2.51%	1.37%	6.95%	-34.38%
OPT	53 Neutral	£190.87M	54.16	―	―	―	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Optima Health PLC Corporate Events

Optima Health PLC Reports Strong Revenue Growth and Strategic Acquisitions

Optima Health PLC reported a 17% increase in revenue to £59.5 million for the six months ending September 2025, driven by strategic acquisitions and new contract wins. The company completed the acquisition of Cognate Health in Ireland and Care first’s Employee Assistance Business, enhancing its service offerings and geographic reach. Despite a slight decrease in adjusted EBITDA, Optima Health has a strong business pipeline and is undergoing a transformation program to improve margins and operational efficiency. The company is well-positioned to capitalize on market opportunities, with plans to grow revenue to £200 million and adjusted EBITDA to £40 million in the medium term.

The most recent analyst rating on (GB:OPT) stock is a Buy with a £225.00 price target. To see the full list of analyst forecasts on Optima Health PLC stock, see the GB:OPT Stock Forecast page.

Optima Health PLC to Announce Half Year Results on 10 December 2025

Optima Health PLC has announced that it will release its Half Year Results for the period ending 30 September 2025 on 10 December 2025. The announcement will be accompanied by an in-person briefing for analysts, hosted by CEO Jonathan Thomas and CFO Heidi Giles, with additional access via a live webcast and conference call. This upcoming release is significant for stakeholders as it will provide insights into the company’s financial performance and strategic positioning in the health and wellbeing sector.

The most recent analyst rating on (GB:OPT) stock is a Buy with a £225.00 price target. To see the full list of analyst forecasts on Optima Health PLC stock, see the GB:OPT Stock Forecast page.

Optima Health Reports Strong Half-Year Growth and Strategic Acquisitions

Optima Health PLC reported a 17% revenue growth for the half year ending September 2025, reaching approximately £59 million, aligning with market expectations. The company has made strategic acquisitions, including Cognate Health in Ireland and Care first Employee Assistance Business, to enhance its market share and capabilities. These moves mark Optima’s entry into international markets and strengthen its UK presence. The company is also investing in technology to improve its platform, aiming to drive organic growth and improve margins. Optima’s ongoing £210 million contract with the UK Armed Forces and a strong pipeline of new opportunities further solidify its position as a leading occupational health provider.

The most recent analyst rating on (GB:OPT) stock is a Buy with a £225.00 price target. To see the full list of analyst forecasts on Optima Health PLC stock, see the GB:OPT Stock Forecast page.

Optima Health Reports Strong Half-Year Growth and Strategic Acquisitions

Optima Health PLC has reported a 17% revenue growth for the first half of 2025, reaching approximately £59 million, aligning with market expectations. The company has made strategic acquisitions, including Cognate Health in Ireland and Care first Employee Assistance Business, to expand its market reach and capabilities. These moves are part of Optima’s strategy to enhance its platform and improve margins, positioning itself for further growth in the UK and internationally. The company’s robust financial position and ongoing investments in technology are expected to drive organic growth and reinforce its market leadership in occupational health and wellbeing solutions.

The most recent analyst rating on (GB:OPT) stock is a Buy with a £225.00 price target. To see the full list of analyst forecasts on Optima Health PLC stock, see the GB:OPT Stock Forecast page.